Assurant vs RenaissanceRe
AIZ and RNR side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AIZ and RNR compare
Assurant and RenaissanceRe are about the same size, with market caps of $15.9B and $14.2B.
On earnings, RenaissanceRe is cheaper: it trades at 10.0× trailing earnings, against 15.3× for Assurant.
Assurant grew revenue faster over the last twelve months (9.4% versus −20.9% for RenaissanceRe).
RenaissanceRe keeps more of each dollar of sales as profit, with a net margin of 16.2% compared with 7.9% at Assurant.
Both pay dividends: Assurant yields 1.1% and RenaissanceRe 0.35%.
Assurant scores higher on the StockData Score (13 against 9 for RenaissanceRe), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AIZ | RNR |
|---|---|---|
| Size and price | ||
| Market cap | $15.9B | $14.2B |
| Share price | $322.16 | $352.18 |
| Change, 1 year | 40.9% | 33.6% |
| Change, 5 years | 105% | 126% |
| Beta (5Y) | 0.32 | −0.03 |
| Employees | 15K | 1,040 |
| StockData Score | ||
| Total score | 13 (better) | 9 |
| Valuation score | 0 | 2 (better) |
| Growth score | 4 (better) | 1 |
| Performance score | 5 (better) | 4 |
| Health score | 0 | 0 |
| Dividend score | 4 (better) | 2 |
| Valuation | ||
| P/E | 15.3× | 10.0× (better) |
| P/S | 1.2× (better) | 1.5× |
| P/B | 2.6× | 1.3× (better) |
| EV/EBITDA | 8.3× | 4.5× (better) |
| P/FCF | 9.6× | – |
| PEG | 0.31 | – |
| FCF yield | 10.4% | – |
| Fair value | $240.97 | $333.09 |
| Margin of safety | −33.7% | −5.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 9.4% (better) | −20.9% |
| Revenue growth, 5Y average | 6.0% | 20.0% (better) |
| Net income growth (TTM) | 48.3% (better) | −9.7% |
| EPS growth (TTM) | 51.0% (better) | −1.7% |
| EPS growth, 5Y average | 19.4% | 29.6% (better) |
| Profitability | ||
| Net margin | 7.9% | 16.2% (better) |
| FCF margin | 12.3% | – |
| Return on equity | 18.3% (better) | 13.7% |
| Financial health | ||
| Altman Z-score | 0.89 (better) | 0.68 |
| Piotroski F-score | 7 | 7 |
| Dividends and buybacks | ||
| Dividend yield | 1.1% (better) | 0.35% |
| Payout ratio | 16.6% | 4.4% |
| Years of dividend growth | 16 | – |
| Dividend growth, 5Y average | 5.2% | – |
| Buyback yield | 2.4% | 11.8% (better) |
| Shareholder yield | 3.5% | 12.1% (better) |
| Ownership | ||
| Held by institutions | 98.6% | 103% |
| Held by insiders | 0.78% | 2.4% |
| Insider net buying, 12 months | −$13.3M (better) | −$16.2M |
| Superinvestors holding | – | 2 |
| Short interest, % of float | – | 3.0% |
Go deeper
- AIZ stock overview
- AIZ income statement
- AIZ valuation and score
- RNR stock overview
- RNR income statement
- RNR valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.